Apollomics Inc. Warrant - APLMW STOCK NEWS

Apollomics Inc. (Nasdaq: APLM) announced the presentation of vebreltinib efficacy and safety data from the ongoing multi-cohort Phase 2 KUNPENG trial (NCT04258033) and the ongoing global multi-cohort Phase 2 SPARTA trial (NCT03175224) at the 2023 IASLC North America Conference on Lung Cancer (NACLC). Vebreltinib appears efficacious in non-small cell lung cancer (NSCLC) patients with MetExon14 skipping mutation with or without co-occurring MET amplification. The preliminary data from NSCLC patients with MetExon14 skipping mutation from the KUNPENG and SPARTA trials showed the following efficacy and safety results: ORR in patients without co-occurring MET amplification (gene copy number<4, n=76) was 64.5%, with median DOR of 15.9 months and Disease Control Rate (DCR) of 88%. ORR in patients with MET amplification (GCN≥4, n=7) was 85.7%, with DCR of 100%. mDOR was not reached. Treatment-related adverse events of grade 3 or higher were reported in 42.2% of patients, with the most common being edema (13.3%) and ALT increase (7.2%).

Apollomics Inc. (APL) to participate in Fireside Chat at H.C. Wainwright 4th Annual Precision Oncology Virtual Conference. Co-Founders Dr. Guo-Liang Yu and Dr. Sanjeev Redkar will discuss the company's oncology drug candidates for difficult-to-treat cancers.

Apollomics Inc. (APLM) presents clinical results for vebreltinib in the treatment of NSCLC with MET exon 14 skipping mutation at 2023 NACLC

Apollomics Inc. (Nasdaq: APLM) announces that its partner in China, Avistone Biotechnology Co. Ltd., has received conditional approval from the National Medical Products Administration (NMPA) of China for the commercialization of vebreltinib to treat patients with MET exon 14 skipping non-small cell lung cancer (NSCLC). Vebreltinib, a potent c-Met inhibitor, offers a potential breakthrough for patients with MET exon 14 skipping NSCLC and other cancers driven by c-Met alterations. The approval is based on compelling clinical data and supports continued development of vebreltinib for the rest of the world. NSCLC accounts for approximately 85% of all lung cancer cases and remains a leading cause of cancer-related deaths worldwide, making this approval a significant achievement.

Apollomics Inc. announced the addition of two new cohorts in its Phase 2 SPARTA study, evaluating vebreltinib in patients with non-small cell lung cancer and other solid tumors. The first cohort will evaluate vebreltinib in combination with osimertinib for patients with EGFR-mutated NSCLC, while the second cohort will evaluate vebreltinib monotherapy in solid tumors with high expression of c-MET and HGF. The company aims to address treatment resistance resulting from dysregulations in the HGF/c-MET axis.

Apollomics Inc. announces positive clinical results for vebreltinib in treating GBM with PTPRZ-MET fusion at ESMO 2023

Apollomics Inc. presents vebreltinib efficacy and safety data from the KUNPENG clinical trial at ESMO 2023. The drug shows potential as a treatment for cancers driven by MET alterations, particularly in NSCLC with MetEx14 skipping mutation. Efficacy results include an ORR of 75% and a high disease control rate.

Apollomics Inc. announces the availability of vebreltinib data at the ESMO 2023 Congress. The data includes safety and efficacy results from a Phase 2 trial in lung cancer patients with c-MET alterations, as well as preliminary data from a real-life cohort analysis in recurrent glioblastoma patients.

Apollomics Inc. announced its financial results for H1 2023, reporting approximately $52.6 million in cash, cash equivalents, and investments at June 30, 2023, with a cash runway to mid-year 2024. The company expects Phase 2 data for vebreltinib in NSCLC patients with MET exon14 skipping mutation in the second half of 2023. The company also highlighted its pipeline progress and upcoming clinical data. However, no specific positive or negative business takes affecting the stock price were mentioned in the PR.